Salud financiera de hoja de balance de Catalyst Pharmaceuticals

Salud financiera controles de criterios 6/6

Catalyst Pharmaceuticals tiene un patrimonio de accionistas total de $387.9M y una deuda total de $0.0, lo que sitúa su ratio deuda-patrimonio en 0%. Sus activos y pasivos totales son $470.1M y $82.2M respectivamente. El BAIT de Catalyst Pharmaceuticals es de $86.8M, por lo que su ratio de cobertura de intereses es de -18.6. Tiene efectivo e inversiones a corto plazo que ascienden a $137.6M.

Información clave

Ratio deuda-patrimonio

US$0

Deuda

Ratio de cobertura de intereses	-18.6x
Efectivo	US$137.64m
Patrimonio	US$387.88m
Total pasivo	US$82.23m
Activos totales	US$470.11m

Actualizaciones recientes sobre salud financiera

No hay actualizaciones

Recent updates

Catalyst Pharmaceuticals: Revenue Growth Lagging Expense Growth (Rating Downgrade)

Apr 06

Earnings Tell The Story For Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

Jan 29

Catalyst Pharmaceuticals: Until The TEVA ANDA Is Resolved, There Is A Risk

Jan 17

With EPS Growth And More, Catalyst Pharmaceuticals (NASDAQ:CPRX) Makes An Interesting Case

Sep 06

Should You Be Adding Catalyst Pharmaceuticals (NASDAQ:CPRX) To Your Watchlist Today?

May 27

Do Catalyst Pharmaceuticals' (NASDAQ:CPRX) Earnings Warrant Your Attention?

Feb 13

Is Now The Time To Put Catalyst Pharmaceuticals (NASDAQ:CPRX) On Your Watchlist?

Nov 11

Análisis de la situación financiera

Pasivos a corto plazo: Los activos a corto plazo ($219.3M) de CPRX superan a sus pasivos a corto plazo ($76.1M).

Pasivo a largo plazo: Los activos a corto plazo de CPRX ($219.3M) superan a sus pasivos a largo plazo ($6.2M).

Historial y análisis de deuda-patrimonio

Nivel de deuda: CPRX está libre de deudas.

Reducción de la deuda: CPRX no ha tenido ninguna deuda en los últimos 5 años.

Cobertura de la deuda: CPRX no tiene deuda, por lo tanto no necesita estar cubierta por flujo de caja operativo.

Cobertura de intereses: CPRX no tiene deuda, por lo que la cobertura de pagos de intereses no es motivo de preocupación.

Salud financiera de hoja de balance de Catalyst Pharmaceuticals

Salud financiera controles de criterios 6/6

Información clave

Actualizaciones recientes sobre salud financiera

Recent updates

Catalyst Pharmaceuticals, Inc. to Report Q1, 2024 Results on May 08, 2024

Catalyst Pharmaceuticals, Inc., Annual General Meeting, May 21, 2024

Independent Director notifies of intention to sell stock

Catalyst Pharmaceuticals: Revenue Growth Lagging Expense Growth (Rating Downgrade)

Insider recently sold US$411k worth of stock

Catalyst Pharmaceuticals Announces Agamree® Now Commercially Available in the U.S. for the Treatment of Duchenne Muscular Dystrophy (Dmd)

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Catalyst Pharmaceuticals, Inc. Provides Revenue Guidance for the Year 2024

Catalyst Pharmaceuticals, Inc. to Report Q4, 2023 Results on Feb 28, 2024

Earnings Tell The Story For Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

Catalyst Pharmaceuticals: Until The TEVA ANDA Is Resolved, There Is A Risk

Catalyst Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $150 million.

Co-Founder exercised options to buy US$4.3m worth of stock.

Investor sentiment improves as stock rises 15%

Price target increased by 13% to US$26.20

Catalyst Pharmaceuticals, Inc. Announces Firapse New Drug Application Submitted in Japan by Partner DyDo Pharma

COO & Chief Scientific Officer recently sold US$570k worth of stock

COO & Chief Scientific Officer notifies of intention to sell stock

Catalyst Pharmaceuticals, Inc. Appoints Michael W. Kalb as Its Chief Financial Officer, Effective on January 1, 2024

Catalyst Pharmaceuticals, Inc. Raises Revenue Guidance for the Full Year 2023

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Catalyst Pharmaceuticals, Inc. Receives Two New U.S. Patent Allowances for FIRDAPSE

Catalyst Pharmaceuticals, Inc. Reports FDA Approval of AGAMREE® (vamorolone) for Duchenne Muscular Dystrophy Granted to Santhera Pharmaceuticals

Catalyst Pharmaceuticals, Inc. to Report Q3, 2023 Results on Nov 08, 2023

Catalyst Pharmaceuticals, Inc. Announces Chief Executive Officer Changes

Consensus EPS estimates fall by 17%

Catalyst Pharmaceuticals, Inc. Announces FDA Acceptance of the Supplemental New Drug Application for Firapse

With EPS Growth And More, Catalyst Pharmaceuticals (NASDAQ:CPRX) Makes An Interesting Case

Catalyst Pharmaceuticals, Inc. Announces the Resignation of Philip H. Coelho as Independent Member of the Board

Catalyst Pharmaceuticals, Inc. Announces Abstract on Lambert Eaton Myasthenic Syndrome (LEMS) to Be Presented at the Upcoming IASLC 2023 World Conference of Lung Cancer

Second quarter 2023 earnings released: EPS: US$0.35 (vs US$0.21 in 2Q 2022)

Catalyst Pharmaceuticals, Inc. Provides Revenue Guidance for the Year 2023

Catalyst Pharmaceuticals, Inc. Announces Resignation of Patrick J. Mcenany as Chief Executive Officer

Catalyst Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 09, 2023

Catalyst Pharmaceuticals, Inc., Annual General Meeting, Aug 22, 2023

Catalyst Pharmaceuticals Appoints Tamar Thompson to its Board of Directors

Should You Be Adding Catalyst Pharmaceuticals (NASDAQ:CPRX) To Your Watchlist Today?

Consensus EPS estimates fall by 23%

Investor sentiment deteriorates as stock falls 28%

COO & Chief Scientific Officer exercised options to buy US$1.3m worth of stock.

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Catalyst Pharmaceuticals, Inc. Provides Revenue Guidance for the Full Year 2023

Catalyst Pharmaceuticals, Inc. Advances sNDA Submission Plans to Increase Indicated Maximum Dose for FIRDAPSE®? from 80 Mg Per Day to 100 Mg Per Day

Independent Director exercised options and sold US$481k worth of stock

Insider exercised options and sold US$747k worth of stock

Investor sentiment improves as stock rises 15%

Full year 2022 earnings: EPS exceeds analyst expectations

Do Catalyst Pharmaceuticals' (NASDAQ:CPRX) Earnings Warrant Your Attention?

Catalyst Pharmaceuticals, Inc. to Report Q4, 2022 Results on Mar 15, 2023

Investor sentiment deteriorates as stock falls 30%

Investor sentiment improved over the past week

Chief Medical & Regulatory Officer exercised options and sold US$100k worth of stock

Chief Accounting Officer recently sold US$2.0m worth of stock

Independent Director recently sold US$332k worth of stock

Chief Commercial Officer exercised options and sold US$1.9m worth of stock

Price target increased to US$18.10

Price target increased to US$18.10

Is Now The Time To Put Catalyst Pharmaceuticals (NASDAQ:CPRX) On Your Watchlist?

Price target increased to US$17.30

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Catalyst Pharmaceuticals, Inc. Provides Earnings Guidance for the Year 2022

Catalyst Pharmaceuticals, Inc. to Report Q3, 2022 Results on Nov 09, 2022

Catalyst Pharmaceuticals Announces FDA Approval of Supplemental New Drug Application for Firdapse(R) Expanding Patient Population to Include Pediatric Patients

Chief Accounting Officer recently sold US$714k worth of stock

Investor sentiment deteriorated over the past week

Chief Medical & Regulatory Officer exercised options and sold US$1.6m worth of stock

Co-Founder recently sold US$16m worth of stock

Catalyst Pharmaceuticals gains 9% on SmallCap 600 addition

Chief Accounting Officer recently sold US$969k worth of stock

Chief Commercial Officer recently sold US$199k worth of stock

Catalyst Pharma ends momentum as Roth downgrades

Chief Accounting Officer exercised options and sold US$1.7m worth of stock

Investor sentiment improved over the past week

Catalyst Pharmaceuticals: Performing Above Expectations

Catalyst Pharmaceuticals, Inc. Provides Earnings Guidance for the Year 2022